{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:51:25Z","timestamp":1788893485376,"version":"build-2803163510"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172230"],"award-info":[{"award-number":["82172230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Development Plan Project of Jilin Province","award":["20240205001YY"],"award-info":[{"award-number":["20240205001YY"]}]},{"name":"the College Students\u2019 Innovative Entrepreneurial Training Plan Program","award":["X202410183444"],"award-info":[{"award-number":["X202410183444"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-025-04133-8","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:45:59Z","timestamp":1737629159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mesenchymal stromal cell exosomes for drug delivery of prostate cancer treatments: a review"],"prefix":"10.1186","volume":"16","author":[{"given":"Chengran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinao","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingguo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baisong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-875X","authenticated-orcid":false,"given":"Jinlan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"10437","key":"4133_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James ND, Tannock I, N\u2019Dow J, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. 2024;403(10437):1634.","journal-title":"The Lancet"},{"issue":"17","key":"4133_CR2","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"6","key":"4133_CR3","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4133_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.clgc.2022.09.003","volume":"21","author":"TA Pattenden","year":"2023","unstructured":"Pattenden TA, Samaranayke D, Morton A, et al. Modern active surveillance in prostate cancer: a narrative review. Clin Genitourin Cancer. 2023;21(1):115\u201323.","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"4133_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s10147-022-02278-7","volume":"28","author":"T Kirisawa","year":"2023","unstructured":"Kirisawa T, Shiota M, Kimura T, et al. Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy. Int J Clin Oncol. 2023;28(2):306\u201313.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4133_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/nau.23845","volume":"38","author":"MA Averbeck","year":"2019","unstructured":"Averbeck MA, Woodhouse C, Comiter C, et al. Surgical treatment of post-prostatectomy stress urinary incontinence in adult men: report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019;38(1):398\u2013406.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"4133_CR7","volume":"14","author":"YF Chin","year":"2022","unstructured":"Chin YF, Lynn N. Systematic review of focal and salvage cryotherapy for prostate cancer. Cureus. 2022;14(6): e26400.","journal-title":"Cureus"},{"issue":"3","key":"4133_CR8","first-page":"231","volume":"71","author":"J Mayor de Castro","year":"2018","unstructured":"Mayor de Castro J, Ca\u00f1o Velasco J, Arag\u00f3n Chamizo J, Andr\u00e9s Boville G, Herranz Amo F, Hern\u00e1ndez Fern\u00e1ndez C. C\u00e1ncer de pr\u00f3stata localmente avanzado. Definici\u00f3n, diagn\u00f3stico y tratamiento [Locally advanced prostate cancer. Definition, diagnosis and treatment]. Arch Esp Urol. 2018;71(3):231\u20138.","journal-title":"Arch Esp Urol"},{"issue":"6","key":"4133_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","volume":"82","author":"T Yanagisawa","year":"2022","unstructured":"Yanagisawa T, Rajwa P, Thibault C, et al. Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur Urol. 2022;82(6):584\u201398.","journal-title":"Eur Urol"},{"issue":"1","key":"4133_CR10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-024-02962-8","volume":"43","author":"B Cheng","year":"2024","unstructured":"Cheng B, Li L, Luo T, et al. Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1\/STAT4 pathway. J Exp Clin Cancer Res. 2024;43(1):67.","journal-title":"J Exp Clin Cancer Res"},{"key":"4133_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","volume":"518","author":"A Jamroze","year":"2021","unstructured":"Jamroze A, Chatta G, Tang DG. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 2021;518:1\u20139.","journal-title":"Cancer Lett"},{"issue":"6","key":"4133_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","volume":"5","author":"D Menges","year":"2022","unstructured":"Menges D, Yebyo HG, Sivec-Muniz S, et al. Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment. Eur Urol Oncol. 2022;5(6):605\u201316.","journal-title":"Eur Urol Oncol"},{"issue":"5928","key":"4133_CR13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787\u201390.","journal-title":"Science"},{"issue":"10","key":"4133_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/stem.3248","volume":"38","author":"JW Park","year":"2020","unstructured":"Park JW, Fu S, Huang B, Xu RH. Alternative splicing in mesenchymal stem cell differentiation. Stem Cells. 2020;38(10):1229\u201340.","journal-title":"Stem Cells"},{"issue":"5","key":"4133_CR15","doi-asserted-by":"publisher","first-page":"\u010327","DOI":"10.1101\/cshperspect.a030627","volume":"9","author":"NJ Venturini","year":"2019","unstructured":"Venturini NJ, Drake CG. Immunotherapy for prostate cancer. Cold Spring Harb Perspect Med. 2019;9(5):\u010327.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"4133_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12032-022-01781-1","volume":"39","author":"SZ Rasihashemi","year":"2022","unstructured":"Rasihashemi SZ, Sahrai H, Rezazadeh-Gavgani E, Yazdani Y, Khalaji A, Lotfinejad P. Exos carrying immune checkpoints, a promising therapeutic approach in cancer treatment. Med Oncol. 2022;39(12):183.","journal-title":"Med Oncol"},{"issue":"1","key":"4133_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12943-022-01650-5","volume":"21","author":"Z Lin","year":"2022","unstructured":"Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. Mesenchymal stem cell-derived Exos in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2022;21(1):179.","journal-title":"Mol Cancer"},{"issue":"21","key":"4133_CR18","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.3390\/cells11213366","volume":"11","author":"C McLaughlin","year":"2022","unstructured":"McLaughlin C, Datta P, Singh YP, et al. Mesenchymal stem cell-derived extracellular vesicles for therapeutic use and in bioengineering applications. Cells. 2022;11(21):3366.","journal-title":"Cells"},{"issue":"8","key":"4133_CR19","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/pharmaceutics15082042","volume":"15","author":"HB Koh","year":"2023","unstructured":"Koh HB, Kim HJ, Kang S-W, Yoo T-H. Exosome-based drug delivery: translation from bench to clinic. Pharmaceutics. 2023;15(8):2042.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4133_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-020-03296-8","volume":"39","author":"J Walz","year":"2021","unstructured":"Walz J, Pignot G, Fakhfakh S, et al. Metastatic hormone sensitive prostate cancer: local treatment strategies. World J Urol. 2021;39(2):327\u201337.","journal-title":"World J Urol"},{"issue":"Pt 1","key":"4133_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.semcancer.2021.08.004","volume":"86","author":"V Vlaeminck-Guillem","year":"2022","unstructured":"Vlaeminck-Guillem V. Exos and prostate cancer management. Semin Cancer Biol. 2022;86(Pt 1):101\u201311.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"4133_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55\u201370.","journal-title":"Acta Pharm Sin B"},{"key":"4133_CR23","doi-asserted-by":"publisher","first-page":"9962194","DOI":"10.1155\/2021\/9962194","volume":"2021","author":"Z Sun","year":"2021","unstructured":"Sun Z, Zhang J, Li J, et al. Roles of mesenchymal stem cell-derived exos in cancer development and targeted therapy. Stem Cells Int. 2021;2021:9962194.","journal-title":"Stem Cells Int"},{"key":"4133_CR24","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S444582","volume":"18","author":"J Tian","year":"2023","unstructured":"Tian J, Han Z, Song D, et al. Engineered exosome for drug delivery: recent development and clinical applications. Int J Nanomed. 2023;18:7923\u201340.","journal-title":"Int J Nanomed"},{"key":"4133_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.actbio.2020.06.036","volume":"113","author":"F Mehryab","year":"2020","unstructured":"Mehryab F, Rabbani S, Shahhosseini S, et al. Exos as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges. Acta Biomater. 2020;113:42\u201362.","journal-title":"Acta Biomater"},{"issue":"2","key":"4133_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10544-019-0396-7","volume":"21","author":"S Busatto","year":"2019","unstructured":"Busatto S, Pham A, Suh A, Shapiro S, Wolfram J. Organotropic drug delivery: synthetic nanoparticles and extracellular vesicles. Biomed Microdevices. 2019;21(2):46.","journal-title":"Biomed Microdevices"},{"issue":"6478","key":"4133_CR27","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology, function, and biomedical applications of Exos. Science. 2020;367(6478):eaau6977.","journal-title":"Science"},{"issue":"28","key":"4133_CR28","doi-asserted-by":"publisher","first-page":"44462","DOI":"10.18632\/oncotarget.9852","volume":"7","author":"F Alcayaga-Miranda","year":"2016","unstructured":"Alcayaga-Miranda F, Gonz\u00e1lez PL, Lopez-Verrilli A, et al. Prostate tumor-induced angiogenesis is blocked by Exos derived from menstrual stem cells through the inhibition of reactive oxygen species. Oncotarget. 2016;7(28):44462\u201377.","journal-title":"Oncotarget"},{"key":"4133_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112171","volume":"134","author":"F Lavi Arab","year":"2024","unstructured":"Lavi Arab F, Hoseinzadeh A, Hafezi F, et al. Mesenchymal stem cell-derived Exos for management of prostate cancer: an updated view. Int Immunopharmacol. 2024;134: 112171.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4133_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13045-020-00987-y","volume":"13","author":"L Zhu","year":"2020","unstructured":"Zhu L, Sun HT, Wang S, et al. Isolation and characterization of Exos for cancer research. J Hematol Oncol. 2020;13(1):152.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"4133_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103222","volume":"9","author":"JJ Lai","year":"2022","unstructured":"Lai JJ, Chau ZL, Chen SY, et al. Exosome processing and characterization approaches for research and technology development. Adv Sci (Weinh). 2022;9(15): e2103222.","journal-title":"Adv Sci (Weinh)"},{"key":"4133_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102121","volume":"50","author":"N Dilsiz","year":"2024","unstructured":"Dilsiz N. A comprehensive review on recent advances in exosome isolation and characterization: toward clinical applications. Transl Oncol. 2024;50: 102121.","journal-title":"Transl Oncol"},{"issue":"7","key":"4133_CR33","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3390\/cancers15072186","volume":"15","author":"C Bailly","year":"2023","unstructured":"Bailly C, Thuru X. Targeting of tetraspanin CD81 with monoclonal antibodies and small molecules to combat cancers and viral diseases. Cancers (Basel). 2023;15(7):2186.","journal-title":"Cancers (Basel)."},{"issue":"19","key":"4133_CR34","doi-asserted-by":"publisher","first-page":"eadi9156","DOI":"10.1126\/sciadv.adi9156","volume":"10","author":"Y Ai","year":"2024","unstructured":"Ai Y, Guo C, Garcia-Contreras M, et al. Endocytosis blocks the vesicular secretion of exosome marker proteins. Sci Adv. 2024;10(19):eadi9156.","journal-title":"Sci Adv"},{"issue":"1","key":"4133_CR35","doi-asserted-by":"publisher","first-page":"1766192","DOI":"10.1080\/20013078.2020.1766192","volume":"9","author":"G Chanteloup","year":"2020","unstructured":"Chanteloup G, Cordonnier M, Isambert N, et al. Monitoring HSP70 exosomes in cancer patients\u2019 follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020;9(1):1766192.","journal-title":"J Extracell Vesicles."},{"key":"4133_CR36","doi-asserted-by":"publisher","first-page":"13588","DOI":"10.1038\/ncomms13588","volume":"7","author":"C Villarroya-Beltri","year":"2016","unstructured":"Villarroya-Beltri C, Baixauli F, Mittelbrunn M, et al. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins. Nat Commun. 2016;7:13588.","journal-title":"Nat Commun"},{"issue":"6","key":"4133_CR37","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/15548627.2020.1756557","volume":"16","author":"AM Leidal","year":"2020","unstructured":"Leidal AM, Debnath J. LC3-dependent extracellular vesicle loading and secretion (LDELS). Autophagy. 2020;16(6):1162\u20133.","journal-title":"Autophagy"},{"issue":"4","key":"4133_CR38","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","volume":"56","author":"HI Kim","year":"2024","unstructured":"Kim HI, Park J, Zhu Y, Wang X, Han Y, Zhang D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp Mol Med. 2024;56(4):836\u201349.","journal-title":"Exp Mol Med"},{"issue":"23\u201324","key":"4133_CR39","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1002\/elps.201800526","volume":"40","author":"S Ayala-Mar","year":"2019","unstructured":"Ayala-Mar S, Donoso-Quezada J, Gallo-Villanueva RC, Perez-Gonzalez VH, Gonz\u00e1lez-Valdez J. Recent advances and challenges in the recovery and purification of cellular Exos. Electrophoresis. 2019;40(23\u201324):3036\u201349.","journal-title":"Electrophoresis"},{"key":"4133_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2021.107814","volume":"54","author":"SZ Shirejini","year":"2022","unstructured":"Shirejini SZ, Inci F. The Yin and Yang of exosome isolation methods: conventional practice, microfluidics, and commercial kits. Biotechnol Adv. 2022;54: 107814.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"4133_CR41","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","volume":"27","author":"W Meng","year":"2020","unstructured":"Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585\u201398.","journal-title":"Drug Deliv"},{"issue":"14","key":"4133_CR42","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.3390\/ijms25147715","volume":"25","author":"W Zhao","year":"2024","unstructured":"Zhao W, Li K, Li L, et al. Mesenchymal stem cell-derived exos as drug delivery vehicles in disease therapy. Int J Mol Sci. 2024;25(14):7715.","journal-title":"Int J Mol Sci"},{"key":"4133_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jconrel.2020.07.042","volume":"326","author":"S Salunkhe","year":"2020","unstructured":"Salunkhe S, Dheeraj, Basak M, Chitkara D, Mittal A. Surface functionalization of Exos for target-specific delivery and in vivo imaging and tracking: strategies and significance. J Control Release. 2020;326:599\u2013614.","journal-title":"J Control Release"},{"key":"4133_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.728616","volume":"10","author":"L Chen","year":"2022","unstructured":"Chen L, Wang L, Zhu L, et al. Exos as drug carriers in anti-cancer therapy. Front Cell Dev Biol. 2022;10: 728616.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"4133_CR45","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.7150\/thno.52570","volume":"11","author":"Y Liang","year":"2021","unstructured":"Liang Y, Duan L, Lu J, Xia J. Engineering Exos for targeted drug delivery. Theranostics. 2021;11(7):3183\u201395.","journal-title":"Theranostics"},{"key":"4133_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pharmthera.2017.02.020","volume":"174","author":"L Barile","year":"2017","unstructured":"Barile L, Vassalli G. Exos: therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017;174:63\u201378.","journal-title":"Pharmacol Ther"},{"key":"4133_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.cellbio.19.111301.153609","volume":"19","author":"ME Hemler","year":"2003","unstructured":"Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397\u2013422.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"13","key":"4133_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12164","volume":"10","author":"A Rai","year":"2021","unstructured":"Rai A, Fang H, Claridge B, Simpson RJ, Greening DW. Proteomic dissection of large extracellular vesicle surfaceome unravels interactive surface platform. J Extracell Vesicles. 2021;10(13): e12164.","journal-title":"J Extracell Vesicles"},{"key":"4133_CR49","volume":"37","author":"N Palomar-Alonso","year":"2023","unstructured":"Palomar-Alonso N, Lee M, Kim M. Exos: membrane-associated proteins, challenges and perspectives. Biochem Biophys Rep. 2023;37: 101599.","journal-title":"Biochem Biophys Rep"},{"key":"4133_CR50","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","volume":"88","author":"DM Pegtel","year":"2019","unstructured":"Pegtel DM, Gould SJ. Exos. Annu Rev Biochem. 2019;88:487\u2013514.","journal-title":"Annu Rev Biochem"},{"key":"4133_CR51","doi-asserted-by":"publisher","first-page":"31027","DOI":"10.3402\/jev.v5.31027","volume":"5","author":"ME Hung","year":"2016","unstructured":"Hung ME, Leonard JN. A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles. 2016;5:31027.","journal-title":"J Extracell Vesicles"},{"issue":"12","key":"4133_CR52","doi-asserted-by":"publisher","first-page":"10267","DOI":"10.3390\/ijms241210267","volume":"24","author":"M Nowak","year":"2023","unstructured":"Nowak M, G\u00f3rczy\u0144ska J, Ko\u0142odzi\u0144ska K, Rubin J, Choroma\u0144ska A. Extracellular vesicles as drug transporters. Int J Mol Sci. 2023;24(12):10267.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4133_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/ijms18030538","volume":"18","author":"MH Rashed","year":"2017","unstructured":"Rashed MH, Bayraktar E, Helal GK, Abd-Ellah MF, Amero P, Chavez-Reyes A, Rodriguez-Aguayo C. Exos: from garbage bins to promising therapeutic targets. Int J Mol Sci. 2017;18(3):538.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4133_CR54","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/mi10110750","volume":"10","author":"A Oshchepkova","year":"2019","unstructured":"Oshchepkova A, Neumestova A, Matveeva V, et al. Cytochalasin-B-inducible nanovesicle mimics of natural extracellular vesicles that are capable of nucleic acid transfer. Micromachines (Basel). 2019;10(11):750.","journal-title":"Micromachines (Basel)"},{"issue":"10","key":"4133_CR55","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s13346-021-01087-1","volume":"12","author":"J He","year":"2022","unstructured":"He J, Ren W, Wang W, Han W, Jiang L, Zhang D, Guo M. Exosomal targeting and its potential clinical application. Drug Deliv Transl Res. 2022;12(10):2385\u2013402.","journal-title":"Drug Deliv Transl Res"},{"issue":"6478","key":"4133_CR56","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"R Kalluri","year":"2020","unstructured":"Kalluri R, LeBleu VS. The biology,\u00a0function,\u00a0and biomedical applications of Exos. Science. 2020;367(6478):eaau6977.","journal-title":"Science"},{"issue":"1","key":"4133_CR57","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"PC Dinh","year":"2020","unstructured":"Dinh PC, Paudel D, Brochu H, Popowski KD, Gracieux MC, Cores J, Huang K, Hensley MT, Harrell E, Vandergriff AC, George AK, Barrio RT, Hu S, Allen TA, Blackburn K, Caranasos TG, Peng X, Schnabel LV, Adler KB, Lobo LJ, Goshe MB, Cheng K. Inhalation of lung spheroid cell secretome and Exos promotes lung repair in pulmonary fibrosis. Nat Commun. 2020;11(1):1064.","journal-title":"Nat Commun"},{"issue":"1","key":"4133_CR58","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12951-024-02704-0","volume":"22","author":"S Liu","year":"2024","unstructured":"Liu S, Shang W, Song J, Li Q, Wang L. Integration of photomagnetic bimodal imaging to monitor an autogenous exosome loaded platform: unveiling strong targeted retention effects for guiding the photothermal and magnetothermal therapy in a mouse prostate cancer model. J Nanobiotechnol. 2024;22(1):421.","journal-title":"J Nanobiotechnol"},{"issue":"19","key":"4133_CR59","first-page":"3052","volume":"27","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Yu M, Liu L, Tian W. Recent advances of engineered Exos and challenges on clinical translational research. Chin J Tissue Eng Res. 2023;27(19):3052\u201360.","journal-title":"Chin J Tissue Eng Res"},{"issue":"4","key":"4133_CR60","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.apsb.2022.11.019","volume":"13","author":"N Uddin","year":"2023","unstructured":"Uddin N, Binzel DW, Shu D, Fu TM, Guo P. Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome. Acta Pharm Sin B. 2023;13(4):1383\u201399.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"4133_CR61","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/ph16040571","volume":"16","author":"M Abdelsalam","year":"2023","unstructured":"Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into exosome transport through the blood-brain barrier and the potential therapeutical applications in brain diseases. Pharmaceuticals (Basel). 2023;16(4):571.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"4133_CR62","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/cas.15948","volume":"114","author":"W Wang","year":"2023","unstructured":"Wang W, Kong P, Feng K, Liu C, Gong X, Sun T, Duan X, Sang Y, Jiang Y, Li X, Zhang L, Tao Z, Liu W. Exosomal miR-222-3p contributes to castration-resistant prostate cancer by activating mTOR signaling. Cancer Sci. 2023;114(11):4252\u201369.","journal-title":"Cancer Sci"},{"issue":"6096","key":"4133_CR63","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816\u201321.","journal-title":"Science"},{"issue":"8","key":"4133_CR64","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99263","volume":"3","author":"M Mendt","year":"2018","unstructured":"Mendt M, Kamerkar S, Sugimoto H, et al. Generation and testing of clinical-grade Exos for pancreatic cancer. JCI Insight. 2018;3(8): e99263.","journal-title":"JCI Insight"},{"issue":"1","key":"4133_CR65","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12906-020-03046-8","volume":"20","author":"PR Matowa","year":"2020","unstructured":"Matowa PR, Gundidza M, Gwanzura L, Nhachi CFB. A survey of ethnomedicinal plants used to treat cancer by traditional medicine practitioners in Zimbabwe. BMC Complement Med Ther. 2020;20(1):278.","journal-title":"BMC Complement Med Ther"},{"key":"4133_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-1-4939-3584-0_29","volume":"1416","author":"RC Lai","year":"2016","unstructured":"Lai RC, et al. Isolation and characterization of exosome from human embryonic stem cell-derived c-Myc-immortalized mesenchymal stem cells. Methods Mol Biol. 2016;1416:477\u201394.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"4133_CR67","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12964-022-01017-9","volume":"21","author":"E Oveili","year":"2023","unstructured":"Oveili E, Vafaei S, Bazavar H, et al. The potential use of mesenchymal stem cells-derived Exos as microRNAs delivery systems in different diseases. Cell Commun Signal. 2023;21(1):20.","journal-title":"Cell Commun Signal"},{"issue":"17","key":"4133_CR68","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.3390\/cancers13174435","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Jang H, Cho H, et al. Recent advances in exosome-based drug delivery for cancer therapy. Cancers (Basel). 2021;13(17):4435.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4133_CR69","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.biotechadv.2018.09.001","volume":"36","author":"DB Patel","year":"2018","unstructured":"Patel DB, et al. Towards rationally designed biomanufacturing of therapeutic extracellular vesicles: impact of the bioproduction microenvironment. Biotechnol Adv. 2018;36(8):2051\u20139.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"4133_CR70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1186\/s13287-021-02629-7","volume":"12","author":"Y Sun","year":"2021","unstructured":"Sun Y, Liu G, Zhang K, Cao Q, Liu T, Li J. Mesenchymal stem cells-derived Exos for drug delivery. Stem Cell Res Ther. 2021;12(1):561.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4133_CR71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13046-017-0561-x","volume":"36","author":"R Ye","year":"2017","unstructured":"Ye R, Pi M, Cox JV, Nishimoto SK, Quarles LD. CRISPR\/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. J Exp Clin Cancer Res. 2017;36(1):90.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4133_CR72","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41467-021-20962-6","volume":"12","author":"JJ McGuire","year":"2021","unstructured":"McGuire JJ, Frieling JS, Lo CH, et al. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nat Commun. 2021;12(1):723.","journal-title":"Nat Commun"},{"key":"4133_CR73","doi-asserted-by":"publisher","first-page":"31027","DOI":"10.3402\/jev.v5.31027","volume":"5","author":"ME Hung","year":"2016","unstructured":"Hung ME, Leonard JN. A platform for actively loading cargo RNA to elucidate limiting steps in EV-mediated delivery. J Extracell Vesicles. 2016;5:31027.","journal-title":"J Extracell Vesicles."},{"key":"4133_CR74","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.2174\/13816128113199990375","volume":"19","author":"AD Friedman","year":"2013","unstructured":"Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr Pharm Des. 2013;19:6315\u201329.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"4133_CR75","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3390\/molecules25010112","volume":"25","author":"S Bayda","year":"2019","unstructured":"Bayda S, Adeel M, Tuccinardi T, Cordani M, Rizzolio F. The history of nanoscience and nanotechnology: from chemical-physical applications to nanomedicine. Molecules. 2019;25(1):112.","journal-title":"Molecules"},{"issue":"35","key":"4133_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202102150","volume":"17","author":"R Hao","year":"2021","unstructured":"Hao R, Yu Z, Du J, et al. A high-throughput nanofluidic device for exosome nanoporation to develop cargo delivery vehicles. Small. 2021;17(35): e2102150.","journal-title":"Small"},{"key":"4133_CR77","doi-asserted-by":"publisher","first-page":"1299384","DOI":"10.3389\/fonc.2023.1299384","volume":"13","author":"Y Song","year":"2024","unstructured":"Song Y, Song Q, Hu D, et al. The potential applications of artificially modified Exos derived from mesenchymal stem cells in tumor therapy. Front Oncol. 2024;13:1299384.","journal-title":"Front Oncol"},{"issue":"16","key":"4133_CR78","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.1093\/nar\/gkaa683","volume":"48","author":"J Zhuang","year":"2020","unstructured":"Zhuang J, Tan J, Wu C, et al. Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR\/Cas9 system for gene therapy. Nucleic Acids Res. 2020;48(16):8870\u201382.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"4133_CR79","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/nnm-2022-0287","volume":"18","author":"Y Na","year":"2023","unstructured":"Na Y, Zhang N, Zhong X, et al. Polylactic-co-glycolic acid-based nanoparticles modified with peptides and other linkers cross the blood-brain barrier for targeted drug delivery. Nanomedicine (Lond). 2023;18(2):125\u201343.","journal-title":"Nanomedicine (Lond)"},{"issue":"19","key":"4133_CR80","doi-asserted-by":"publisher","first-page":"17581","DOI":"10.1007\/s00432-023-05450-2","volume":"149","author":"Z Guo","year":"2023","unstructured":"Guo Z, Wang G, Yun Z, et al. Global research trends in tumor stem cell-derived Exos and tumor microenvironment: visualization biology analysis. J Cancer Res Clin Oncol. 2023;149(19):17581\u201395.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"4133_CR81","first-page":"75","volume":"1846","author":"KB Johnsen","year":"2014","unstructured":"Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A comprehensive overview of Exos as drug delivery vehicles\u2014endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta. 2014;1846(1):75\u201387.","journal-title":"Biochim Biophys Acta"},{"key":"4133_CR82","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijbiomac.2017.02.012","volume":"98","author":"M Aliabadi","year":"2017","unstructured":"Aliabadi M, Shagholani H, Yunessnia LA. Synthesis of a novel biocompatible nanocomposite of graphene oxide and magnetic nanoparticles for drug delivery. Int J Biol Macromol. 2017;98:287\u201391.","journal-title":"Int J Biol Macromol"},{"key":"4133_CR83","doi-asserted-by":"publisher","first-page":"329","DOI":"10.12688\/f1000research.132186.1","volume":"12","author":"D Ramesh","year":"2023","unstructured":"Ramesh D, Bakkannavar S, Bhat VR, Sharan K. Extracellular vesicles as novel drug delivery systems to target cancer and other diseases: recent advancements and future perspectives. F1000Research. 2023;12:329.","journal-title":"F1000Research"},{"key":"4133_CR84","doi-asserted-by":"publisher","first-page":"31053","DOI":"10.3402\/jev.v5.31053","volume":"5","author":"SA Kooijmans","year":"2016","unstructured":"Kooijmans SA, Aleza CG, Roffler SR, van Solinge WW, Vader P, Schiffelers RM. Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles. 2016;5:31053.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"4133_CR85","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12951-022-01636-x","volume":"20","author":"Y Lin","year":"2022","unstructured":"Lin Y, Yan M, Bai Z, et al. Huc-MSC-derived Exos modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnol. 2022;20(1):432.","journal-title":"J Nanobiotechnol"},{"key":"4133_CR86","doi-asserted-by":"publisher","first-page":"1115786","DOI":"10.3389\/fcell.2022.1115786","volume":"10","author":"A Salehpour","year":"2023","unstructured":"Salehpour A, Balmagambetova S, Mussin N, Kaliyev A, Rahmanifar F. Mesenchymal stromal\/stem cell-derived Exos and genitourinary cancers: a mini review. Front Cell Dev Biol. 2023;10:1115786.","journal-title":"Front Cell Dev Biol"},{"issue":"Pt B","key":"4133_CR87","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","volume":"220","author":"H Saari","year":"2015","unstructured":"Saari H, L\u00e1zaro-Ib\u00e1\u00f1ez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220(Pt B):727\u201337.","journal-title":"J Control Release"},{"issue":"20","key":"4133_CR88","doi-asserted-by":"publisher","first-page":"23396","DOI":"10.1021\/acsami.1c02822","volume":"13","author":"J Du","year":"2021","unstructured":"Du J, Shao Y, Hu Y, et al. Multifunctional liposomes enable active targeting and twinfilin 1 silencing to reverse paclitaxel resistance in brain metastatic breast cancer. ACS Appl Mater Interfaces. 2021;13(20):23396\u2013409.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"7","key":"4133_CR89","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.3390\/ijms25073645","volume":"25","author":"X Wang","year":"2024","unstructured":"Wang X, Li D, Li G, et al. Enhanced therapeutic potential of hybrid Exos loaded with paclitaxel for cancer therapy. Int J Mol Sci. 2024;25(7):3645.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4133_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41420-023-01696-4","volume":"9","author":"M Canovai","year":"2023","unstructured":"Canovai M, Evangelista M, Mercatanti A, et al. Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells. Cell Death Discov. 2023;9(1):445.","journal-title":"Cell Death Discov"},{"issue":"1","key":"4133_CR91","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12951-022-01526-2","volume":"20","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Zheng Y, Zhu Y, Li H, Zhu H, Liu T. Docetaxel-loaded M1 macrophage-derived Exos for a safe and efficient chemoimmunotherapy of breast cancer. J Nanobiotechnol. 2022;20(1):359.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"4133_CR92","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.nano.2015.10.012","volume":"12","author":"MS Kim","year":"2016","unstructured":"Kim MS, Haney MJ, Zhao Y, et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine. 2016;12(3):655\u201364.","journal-title":"Nanomedicine"},{"issue":"1","key":"4133_CR93","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1080\/10717544.2021.1951894","volume":"28","author":"Y Wang","year":"2021","unstructured":"Wang Y, Guo M, Lin D, et al. Docetaxel-loaded Exos for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo. Drug Deliv. 2021;28(1):1510\u201323.","journal-title":"Drug Deliv"},{"key":"4133_CR94","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fonc.2020.00472","volume":"10","author":"QR Guo","year":"2020","unstructured":"Guo QR, Wang H, Yan YD, et al. The role of exosomal microRNA in cancer drug resistance. Front Oncol. 2020;10:472.","journal-title":"Front Oncol"},{"issue":"9","key":"4133_CR95","doi-asserted-by":"publisher","first-page":"256","DOI":"10.31083\/j.fbl2709256","volume":"27","author":"I Kurniawati","year":"2022","unstructured":"Kurniawati I, Liu MC, Hsieh CL, Do AD, Sung SY. Targeting castration-resistant prostate cancer using mesenchymal stem cell Exos for therapeutic MicroRNA-let-7c delivery. Front Biosci (Landmark Ed). 2022;27(9):256.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"4133_CR96","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s13287-019-1442-3","volume":"10","author":"B Sun","year":"2019","unstructured":"Sun B, Ma Y, Wang F, Hu L, Sun Y. miR-644-5p carried by bone mesenchymal stem cell-derived Exos targets regulation of p53 to inhibit ovarian granulosa cell apoptosis. Stem Cell Res Ther. 2019;10(1):360.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"4133_CR97","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41422-021-00491-z","volume":"31","author":"Z Fu","year":"2021","unstructured":"Fu Z, Zhang X, Zhou X, et al. In vivo self-assembled small RNAs as a new generation of RNAi therapeutics. Cell Res. 2021;31(6):631\u201348.","journal-title":"Cell Res"},{"issue":"8","key":"4133_CR98","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41551-021-00725-w","volume":"5","author":"Z Yang","year":"2021","unstructured":"Yang Z, Shi J, Xie J, et al. Large-scale generation of functional mRNA-encapsulating Exos via cellular nanoporation. Nat Biomed Eng. 2021;5(8):944\u20135.","journal-title":"Nat Biomed Eng."},{"key":"4133_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","volume":"318","author":"L Zhao","year":"2020","unstructured":"Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release. 2020;318:1\u201315.","journal-title":"J Control Release"},{"issue":"10","key":"4133_CR100","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1007\/s11064-023-03968-y","volume":"48","author":"X Zhang","year":"2023","unstructured":"Zhang X, Sang X, Chen Y, Yu H, Sun Y, Liang X, Zheng X, Wang X, Yang H, Bi J, Zhang L, Wang P. VCAM-1+ hUC-MSCs exert considerable neuroprotection against cerebral infarction in rats by suppression of NLRP3-induced pyroptosis. Neurochem Res. 2023;48(10):3084\u201398.","journal-title":"Neurochem Res"},{"key":"4133_CR101","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.actbio.2021.12.002","volume":"140","author":"ZS Gao","year":"2022","unstructured":"Gao ZS, Zhang CJ, Xia N, et al. Berberine-loaded M2 macrophage-derived Exos for spinal cord injury therapy. Acta Biomater. 2022;140:745\u20136.","journal-title":"Acta Biomater"},{"issue":"8","key":"4133_CR102","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.apsb.2019.11.013","volume":"10","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Zhou W, Chen X, et al. Bone marrow mesenchymal stem cells-derived Exos for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B. 2020;10(8):1563\u201375.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"4133_CR103","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12951-019-0563-2","volume":"18","author":"G Liang","year":"2020","unstructured":"Liang G, Zhu Y, Ali DJ, et al. Engineered Exos for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnol. 2020;18(1):10.","journal-title":"J Nanobiotechnol"},{"key":"4133_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121621","volume":"322","author":"M Basak","year":"2023","unstructured":"Basak M, Sahoo B, Chaudhary DK, et al. Human umbilical cord blood-mesenchymal stem cell derived Exos as an efficient nanocarrier for Docetaxel and miR-125a: formulation optimization and anti-metastatic behaviour. Life Sci. 2023;322: 121621.","journal-title":"Life Sci"},{"issue":"9","key":"4133_CR105","doi-asserted-by":"publisher","first-page":"256","DOI":"10.31083\/j.fbl2709256","volume":"27","author":"I Kurniawati","year":"2022","unstructured":"Kurniawati I, Liu MC, Hsieh CL, Do AD, Sung SY. Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic MicroRNA-let-7c delivery. Front Biosci (Landmark Ed). 2022;27(9):256.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"14","key":"4133_CR106","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1039\/D4BM00558A","volume":"12","author":"X Fan","year":"2024","unstructured":"Fan X, Zhang Y, Liu W, et al. A comprehensive review of engineered Exos from the preparation strategy to therapeutic applications. Biomater Sci. 2024;12(14):3500\u201321.","journal-title":"Biomater Sci"},{"issue":"5\u20136","key":"4133_CR107","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/bfgp\/elaa018","volume":"19","author":"X Cheng","year":"2020","unstructured":"Cheng X, Fan S, Wen C, Du X. CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges. Brief Funct Genom. 2020;19(5\u20136):411.","journal-title":"Brief Funct Genom"},{"issue":"1","key":"4133_CR108","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"CA Lino","year":"2018","unstructured":"Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234\u201357.","journal-title":"Drug Deliv"},{"issue":"11","key":"4133_CR109","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.3390\/ijms22116072","volume":"22","author":"K Horodecka","year":"2021","unstructured":"Horodecka K, D\u00fcchler M. CRISPR\/Cas9: principle, applications, and delivery through extracellular vesicles. Int J Mol Sci. 2021;22(11):6072.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4133_CR110","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","volume":"11","author":"P Gee","year":"2020","unstructured":"Gee P, Lung MSY, Okuzaki Y, et al. Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. Nat Commun. 2020;11(1):1334.","journal-title":"Nat Commun"},{"issue":"12","key":"4133_CR111","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1021\/acssynbio.8b00192","volume":"7","author":"D Lain\u0161\u010dek","year":"2018","unstructured":"Lain\u0161\u010dek D, Kadunc L, Keber MM, Bratkovi\u010d IH, Romih R, Jerala R. Delivery of an artificial transcription regulator dCas9-VPR by extracellular vesicles for therapeutic gene activation. ACS Synth Biol. 2018;7(12):2715\u201325.","journal-title":"ACS Synth Biol"},{"key":"4133_CR112","doi-asserted-by":"publisher","unstructured":"Cheng X, Fan S, Wen C, Du X. CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges [published correction appears in Brief Funct Genomics. 2020 Dec 4;19(5\u20136):411. https:\/\/doi.org\/10.1093\/bfgp\/elaa018]. Brief Funct Genomics. 2020;19(3):209\u2013214.","DOI":"10.1093\/bfgp\/elaa018"},{"key":"4133_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.590470","volume":"11","author":"W Wei","year":"2021","unstructured":"Wei W, Ao Q, Wang X, et al. Mesenchymal stem cell-derived Exos: a promising biological tool in nanomedicine. Front Pharmacol. 2021;11: 590470.","journal-title":"Front Pharmacol"},{"issue":"3","key":"4133_CR114","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41590-019-0577-9","volume":"21","author":"D Lu","year":"2020","unstructured":"Lu D, Liu L, Sun Y, Song J, Yin Q, Zhang G, Qi F, Hu Z, Yang Z, Zhou Z, Hu Y, Zhang L, Ji J, Zhao X, Jin Y, McNutt MA, Yin Y. The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity. Nat Immunol. 2020;21(3):287\u201397.","journal-title":"Nat Immunol"},{"issue":"9","key":"4133_CR115","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","volume":"20","author":"CM Jackson","year":"2019","unstructured":"Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100\u20139.","journal-title":"Nat Immunol"},{"key":"4133_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110405","volume":"120","author":"A Asadirad","year":"2023","unstructured":"Asadirad A, Ghadiri AA, Amari A, Ghasemi Dehcheshmeh M, Sadeghi M, Dehnavi S. Sublingual prophylactic administration of OVA-loaded MSC-derived Exos to prevent allergic sensitization. Int Immunopharmacol. 2023;120: 110405.","journal-title":"Int Immunopharmacol"},{"key":"4133_CR117","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.molimm.2021.08.015","volume":"139","author":"R Dou","year":"2021","unstructured":"Dou R, Zhang X, Xu X, Wang P, Yan B. Mesenchymal stem cell exosomal tsRNA-21109 alleviate systemic lupus erythematosus by inhibiting macrophage M1 polarization. Mol Immunol. 2021;139:106\u201314.","journal-title":"Mol Immunol"},{"issue":"4","key":"4133_CR118","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.3390\/curroncol30040323","volume":"30","author":"SM Lanka","year":"2023","unstructured":"Lanka SM, Zorko NA, Antonarakis ES, Barata PC. Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and beyond. Curr Oncol. 2023;30(4):4246\u201356.","journal-title":"Curr Oncol"},{"key":"4133_CR119","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.2147\/OTT.S159777","volume":"11","author":"K Wang","year":"2018","unstructured":"Wang K, Ruan H, Xu T, et al. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. Onco Targets Ther. 2018;11:3167\u201378.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"4133_CR120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1515\/polyeng-2023-0166","volume":"44","author":"AA Shaikh","year":"2024","unstructured":"Shaikh AA, Datta P, Dastidar P, et al. Biopolymer-based nanocomposites for application in biomedicine: a review. J Polym Eng. 2024;44(2):83\u2013116.","journal-title":"J Polym Eng"},{"issue":"12","key":"4133_CR121","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.3390\/cells10123278","volume":"10","author":"M Kulus","year":"2021","unstructured":"Kulus M, Sibiak R, Stefa\u0144ska K, Zdun M, Wieczorkiewicz M, Piotrowska-Kempisty H, Ja\u015bkowski JM, Bukowska D, Ratajczak K, Zabel M, Mozdziak P, Kempisty B. Mesenchymal stem\/stromal cells derived from human and animal perinatal tissues-origins, characteristics, signaling pathways, and clinical trials. Cells. 2021;10(12):3278.","journal-title":"Cells"},{"issue":"1","key":"4133_CR122","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12015-021-10231-w","volume":"18","author":"U Galderisi","year":"2022","unstructured":"Galderisi U, Peluso G, Di Bernardo G. Clinical trials based on mesenchymal stromal cells are exponentially increasing: where are we in recent years? Stem Cell Rev Rep. 2022;18(1):23\u201336.","journal-title":"Stem Cell Rev Rep"},{"key":"4133_CR123","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2022.05.027","volume":"347","author":"I Kimiz-Gebologlu","year":"2022","unstructured":"Kimiz-Gebologlu I, Oncel SS. Exos: large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Control Release. 2022;347:533\u201343.","journal-title":"J Control Release"},{"issue":"1","key":"4133_CR124","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jcyt.2012.10.002","volume":"15","author":"J Galipeau","year":"2013","unstructured":"Galipeau J. The mesenchymal stromal cells dilemma\u2013does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15(1):2\u20138.","journal-title":"Cytotherapy"},{"issue":"6","key":"4133_CR125","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13401","volume":"56","author":"N Alessio","year":"2023","unstructured":"Alessio N, Acar MB, Squillaro T, Aprile D, Ayaz-G\u00fcner \u015e, Di Bernardo G, Peluso G, \u00d6zcan S, Galderisi U. Progression of irradiated mesenchymal stromal cells from early to late senescence: changes in SASP composition and anti-tumour properties. Cell Prolif. 2023;56(6): e13401.","journal-title":"Cell Prolif"},{"issue":"11","key":"4133_CR126","doi-asserted-by":"publisher","first-page":"1148761","DOI":"10.3389\/fbioe.2023.1148761","volume":"9","author":"Y Siraj","year":"2023","unstructured":"Siraj Y, Galderisi U, Alessio N. Senescence induces fundamental changes in the secretome of mesenchymal stromal cells (MSCs): implications for the therapeutic use of MSCs and their derivates. Front Bioeng Biotechnol. 2023;9(11):1148761.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"4133_CR127","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1365-2567.2007.02743.x","volume":"124","author":"CA Williams","year":"2008","unstructured":"Williams CA, Harry RA, McLeod JD. Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology. 2008;124(1):89\u2013101.","journal-title":"Immunology"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04133-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04133-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:17:17Z","timestamp":1737631037000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04133-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4133"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04133-8","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}